SCHEMBL2264953

SCHEMBL2264953

CC1(N)C2CC3CC1CC(O)(C3)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.39
LMNA P02545 2/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
STAT6 P42226 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
SLC47A1 Q96FL8 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
HSD11B1 P28845 2/20 0.34
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16374917 1.00 PKM (0.39) PKMLMNASLC22A2SLC22A1GRIN2D
SCHEMBL19457925 0.81 HSD11B1 (0.36) PKMGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL13767296 0.81 HSD11B1 (0.36) PKMHSD11B1
SCHEMBL2266104 0.76 PKM (0.38) PKMLMNASLC22A2SLC22A1GRIN2D
SCHEMBL1557250 0.74 HSD11B1 (0.35) PKMHSD11B1
SCHEMBL24760895 0.72 PKM (0.35) PKMLMNASLC22A2SLC22A1GRIN2D
SCHEMBL19796073 0.72 HSD11B1 (0.32) HSD11B1
SCHEMBL24114741 0.72 HSD11B1 (0.32) HSD11B1
SCHEMBL13502418 0.72 SLC1A2 (0.46) PKMHSD11B1THRB
Methyl Alcohol SCHEMBL19283353 0.72 PKM (0.44) PKMLMNASLC22A2SLC22A1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303845-B1 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors SANOFI SA (FR) 2013-09-18 EP disclosed
US-8524737-B2 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2013-09-03 US disclosed
US-8524737-B2 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2013-09-03 US disclosed
US-8524737-B2 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2013-09-03 US disclosed
US-20110190340-A1 BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2011-08-04 US disclosed
US-20110190340-A1 BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190340-A1 BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES RHOT2, MYLK2, ROCK2 PKM 1551/4885LMNA 1407/4885SLC22A2 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.